Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114).
Sakashita H, Uchibori K, Jin Y, Tsutsui T, Honda T, Sakakibara R, Mitsumura T, Nukui Y, Shirai T, Masuo M, Suhara K, Furusawa H, Yamashita T, Ohba T, Saito K, Takagiwa J, Miyashita Y, Inase N, Miyazaki Y. Sakashita H, et al. Among authors: uchibori k. Thorac Cancer. 2022 May;13(9):1267-1275. doi: 10.1111/1759-7714.14376. Epub 2022 Mar 23. Thorac Cancer. 2022. PMID: 35322551 Free PMC article. Clinical Trial.
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
Ariyasu R, Nishikawa S, Uchibori K, Oh-Hara T, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Kitazono S, Yanagitani N, Horiike A, Inase N, Kasahara K, Nishio M, Katayama R. Ariyasu R, et al. Among authors: uchibori k. Lung Cancer. 2018 Mar;117:1-6. doi: 10.1016/j.lungcan.2017.12.018. Epub 2018 Jan 4. Lung Cancer. 2018. PMID: 29496249
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S. Uchibori K, et al. Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23. Lung Cancer. 2018. PMID: 30268482 Clinical Trial.
Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.
Takano N, Ariyasu R, Koyama J, Sonoda T, Saiki M, Kawashima Y, Oguri T, Hisakane K, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Horiike A, Gemma A, Nishio M. Takano N, et al. Among authors: uchibori k. Lung Cancer. 2019 May;131:69-77. doi: 10.1016/j.lungcan.2019.03.008. Epub 2019 Mar 21. Lung Cancer. 2019. PMID: 31027701
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Takahashi K, Seto Y, Okada K, Uematsu S, Uchibori K, Tsukahara M, Oh-Hara T, Fujita N, Yanagitani N, Nishio M, Okubo K, Katayama R. Takahashi K, et al. Among authors: uchibori k. Thorac Cancer. 2020 Mar;11(3):581-587. doi: 10.1111/1759-7714.13299. Epub 2020 Jan 13. Thorac Cancer. 2020. PMID: 31943796 Free PMC article.
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
Tozuka T, Kitazono S, Sakamoto H, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Hasegawa T, Uchibori K, Yanagitani N, Horiike A, Horai T, Seike M, Gemma A, Nishio M. Tozuka T, et al. Among authors: uchibori k. BMC Cancer. 2020 Mar 12;20(1):207. doi: 10.1186/s12885-020-6704-z. BMC Cancer. 2020. PMID: 32164651 Free PMC article.
59 results